Moderate to Severe Crohn's Disease: A Phase 2 Safety and Efficacy Study of ABBV-154
Research type
Research Study
Full title
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of ABBV-154 in Subjects with Moderately to Severely Active Crohn's Disease (CD): AIM-CD
IRAS ID
1004374
Contact name
Bernhard Dodell
Contact email
Sponsor organisation
AbbVie Deutschland GmbH & Co. KG
Eudract number
2021-002869-18
Clinicaltrials.gov Identifier
Research summary
Research Summary
Crohn's disease (CD) is a long-lasting condition causing inflammation that can affect any part of the gut. CD may cause tiredness, loose stools with or without bleeding, abdominal pain, weight loss, and fever. This study evaluates how safe and effective ABBV-154 is in participants treated for moderately to severely active CD. Adverse events and change in the disease activity will be assessed. ABBV-154 is an investigational drug being evaluated for the treatment of CD. In the induction period, there is a 1 in 5 chance that participants will be assigned to placebo. Depending on the dose received in the induction period, there is a 1 in 2 or 1 in 3 chance that participants will be assigned to placebo in the maintenance period. Around 265 participants 18-75 years of age with moderately to severely active CD will be enrolled in the study at approximately 165 sites worldwide. The study is compromised of a 12-week double-blind, placebo-controlled induction period, followed by either a 12-week double-blind re-induction period for non-responders or a 40-week double-blind placebo-controlled maintenance period for responders. In the maintenance period, responders will be randomised to receive subcutaneous placebo or ABBV-154 in 2 different doses every other week. Participants in the placebo group who are initial responders will receive ABBV-154 in the maintenance period.
Summary of Results
https://gbr01.safelinks.protection.outlook.com/?url=https%3A%2F%2Fclick.pstmrk.it%2F3ts%2Fwww.abbvieclinicaltrials.com%252Fstudy%252F%253Fid%253DM20-371%2FNBTI%2Fu5C4AQ%2FAQ%2F697b9054-0cdb-49d8-9c10-53750623b81c%2F2%2FawHEbYLRNF&data=05%7C02%7Cleicestersouth.rec%40hra.nhs.uk%7C122072d5f93846a98a0908dce871b838%7C8e1f0acad87d4f20939e36243d574267%7C0%7C0%7C638640822313243798%7CUnknown%7CTWFpbGZsb3d8eyJWIjoiMC4wLjAwMDAiLCJQIjoiV2luMzIiLCJBTiI6Ik1haWwiLCJXVCI6Mn0%3D%7C0%7C%7C%7C&sdata=gmGxuM3%2FKehfsgxpT2QTBC2MjxKxPePRlQ%2Bz7ngyZzU%3D&reserved=0
REC name
East Midlands - Leicester South Research Ethics Committee
REC reference
22/EM/0091
Date of REC Opinion
6 Jun 2022
REC opinion
Further Information Favourable Opinion